Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
A rare whale is having an encouraging season for births. Scientists warn it might still go extinct - 2She just became the first wheelchair user to travel to space
- 3Watching ‘Home Alone’ with the kids this holiday season? Brace yourself for '6-7.'
- 47 Methods for further developing Rest Quality
- 5‘Nahariya get ready’: Banner displaying Hezbollah threat mounted in Tehran’s Palestine Square
- What to know about voluntary chocolate recall
- A Manual for Pick Dependable Vehicle Rental Administrations For 2024
- From School Dropout to Example of overcoming adversity: My Excursion
- Allow Innovative Progressions To have a Tremendous Effect
- Louisiana seeks California doctor’s extradition, testing the limits of shield laws
- New York to require social media platforms to display mental health warnings
- They died 'doing what they loved': The stories of workers in their 80s who died on the job
- Ocean side Objections: Staggering Waterfront Breaks
- 'Set up an Army Radio station at President’s Residence': Source close to Katz slams Herzog
